Barely Significant
← all excerpts

Efficacy of cabozantinib and sunitinib for the treatment of intermediate/poor risk renal cell carcinoma based upon UK real-world data.

ESMO Real World Data Digit Oncol · 2024 · PMC12836660 · PMID 41646098

Europe PMCDOI
1
hedged sentence
0.0600
closest p · 1.2× alpha
0.0600
boldest claim

The sentences

bordered on significantP = 0.06so close (0.05 < p ≤ 0.1)
Though there was no significant difference between treatments in overall survival (OS) or progression-free survival (PFS) across models, the difference in PFS bordered on significant in a multipredictor analysis (benefit in favour of cabozantinib; P = 0.06).

also in 13 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.